This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information for Great Britain (GB) and Northern Ireland (NI). Click here for Trumenba®▼ (meningococcal group B vaccine (recombinant, adsorbed)) Prescribing Information for GB and NI.
Adverse event reporting information can be found at the bottom of the page.
Meningococcal disease refers to any illness caused by bacteria called Neisseria meningitidis. N. meningitidis is found only in humans.1
To cause disease, the bacterium must survive in the bloodstream, where it has to avoid being killed by host innate immune mechanisms, particularly the complement system.2 It is able to do this through it's unique structure of both an inner (cytoplasmic) membrane and an outer membrane, separated by a cell wall. These structures house the outer membrane surface proteins and the capsular polysaccharide that comprise the main surface antigens of the organism.3 These antigens are the targets of immunological activity from the host organism.
N. meningitidis uses the polysaccharide capsule to evade destruction by the immune system, using a protective shell to prevent binding of the complement system that could otherwise initiate lysis and phagocytosis. The complement-bacterium complex is called the C3b.4 Evasion can be enhanced by other methods including mimicry of host molecules, recruiting factor H and its
Figure 1: Polysaccharide capsule mechanism. Adapted from Tan LKK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010; 362:1511-20.
Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neiserria meningitidis serogroups A, C, W-135 and Y9
The incubation period of meningococcal disease is 3 to 4 days, with a range of 1 to 10 days. The rate at which the disease develops varies between patients.3
Meningococcal disease is generally uncommon. In England, the national Public Health England (PHE) Meningococcal Reference Unit (MRU) confirmed 461 cases of IMD during 2019 to 2020.8 Focal meningococcal disease refers to disease within a localized area.3 This includes pneumonia, arthritis, otitis media, and epiglottitis.3 Whereas invasive meningococcal refers to disease that spreads in the body4, such as meningitis, septicaemia and bacteraemia.3
In 1906, scientists began to recommend anti-meningococcal serum therapy to protect humans against meningococcal disease; a therapy based on antibodies initially derived from the blood of horses, and later from patients, or individuals recovering from meningococcal disease. Antibiotics revolutionised treatment for meningitis however they do not always act fast enough to prevent damage that the bacteria can cause. The UK later introduced a conjugate vaccine against meningococcal disease with the MenC vaccine introduced in 1999.7
Trumenba (meningococcal group B vaccine (recombinant, adsorbed)) is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.10
Browse and register for speaker programs
View materials for you and your patients
Find videos and on-demand webinars
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2021 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
OK, We will need you to sign in before we can determine if you are aligned with a Pﬁzer promotional colleague.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?